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Abstract
Targeting the vasculature remains a promising approach for treating solid tumors; however, the 
mechanisms of tumor neovascularization are diverse and complex. Here we uncover a new 
subpopulation of melanoma cells that express the vascular cell adhesion molecule PECAM1, but 
not VEGFR-2, and participate in a PECAM1-dependent form of vasculogenic mimicry (VM). 
Clonally-derived PECAM1+ tumor cells coalesce to form PECAM1-dependent networks in vitro 
and they generate well-perfused, VEGF-independent channels in mice. The neural crest specifier 
AP-2α is diminished in PECAM1+ melanoma cells and is a transcriptional repressor of PECAM1. 
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Reintroduction of AP-2α into PECAM1+ tumor cells represses PECAM1 and abolishes tube-
forming ability whereas AP-2α knockdown in PECAM1− tumor cells up-regulates PECAM1 
expression and promotes tube formation. Thus, VM-competent subpopulations, rather than all 
cells within a tumor, may instigate VM, supplant host-derived endothelium, and form PECAM1-
dependent conduits that are not diminished by neutralizing VEGF.
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Introduction
Solid tumors require blood vessels for growth, access to oxygen and nutrients, and the 
removal of waste products. Thus, Folkman proposed that anti-angiogenic therapies could be 
used to attack tumor-associated blood vessels and shrink solid tumors 1. Anti-angiogenic 
therapies are typically designed to target vascular endothelial cells (EC) that form tumor 
blood vessels. Therefore, anti-angiogenic drugs should be active against a spectrum of 
cancers. Furthermore, unlike conventional cytotoxic chemotherapy which targets genetically 
unstable and heterogeneous tumor cells, anti-angiogenic therapies target the vasculature 
which theoretically will not acquire drug resistance but should respond predictably to 
angiogenesis inhibition.
Whereas numerous preclinical models have documented the successful use of angiogenesis 
inhibitors to block tumor growth, these studies collectively show that tumors are typically 
only growth delayed, rather than driven into dormancy 2–5. Thus, the tumor vasculature may 
be more complex than previously considered and tumors may have secondary mechanisms 
for re-vascularization 6,7. For example, freshly isolated tumor-specific EC (TEC) from 
different tumor types display multiple abnormalities 8–12. Two tumor-specific modes of 
neovascularization including “transdifferentiation” of stem-like tumor cells and 
vasculogenic mimicry (VM) are also suggested 13–22. These tumor cell autonomous routes 
to neovascularization may underlie some of the dysfunctional features of tumor blood 
vessels and create outlets for escape from angiogenesis inhibition.
VM, initially described in aggressive forms of uveal melanoma, has been documented in 
multiple tumor types and is correlated with poor patient survival 23. Tumor cell-lined 
networks are typically identified in histological sections by periodic acid-Schiff staining of 
matrix-rich channels, which contain blood, with few or no EC present. However, the 
different molecular mechanisms that generate VM-competent tumor cells are unclear and 
how tumor cell-lined conduits are formed and connected with the host vasculature is 
undetermined. Furthermore, it remains controversial whether tumor cells actively engage 
tumor blood vessels in a process resembling EC-mediated angiogenesis or if tumor cells 
simply fill in gaps between neighboring EC in a passive, nonfunctional manner 24.
Bona fide TEC may be identified and isolated from collagenase-dispersed tumors using 
intercellular adhesion molecule-2 (ICAM2) or platelet endothelial cell adhesion molecule 
Dunleavey et al. Page 2













(PECAM1, also known as CD31) antibodies followed by immunomagnetic separation 8,25. 
Using this methodology, we have uncovered a novel subpopulation of PECAM1+ tumor 
cells in melanoma that participate in a PECAM1-dependent form of VM. Unlike previous 
models suggesting that tumor cells contribute to neovascularization through endothelial-like 
differentiation or recapitulation of developmental plasticity, we demonstrate that VM-
competent tumor cells exist as stable, yet hidden subpopulations in heterogeneous 
melanomas 15,26,27. Clean separation of PECAM1− and PECAM1+ clonal populations from 
the same tumor has allowed us to compare and contrast the differential roles these two 
populations play during tumor growth, angiogenesis, and responses to anti-angiogenic 
therapy.
Results
Identification of PECAM1+ tumor cells from B16F10 melanoma
Using PECAM1 immunomagnetic separation of collagenase-dispersed B16F10 melanoma 
allografts 8,28, we enriched a PECAM1+ population to ~ 98% purity, as determined by flow 
cytometry (Fig. 1a, b). Compared to the PECAM1− fraction, the enriched PECAM1+ 
population expressed abundant Pecam1 mRNA by semi-quantitative RT-PCR (Fig. 1c). 
Unexpectedly, VE-cadherin mRNA was not detected in the PECAM1+ fraction, in contrast 
to mouse dermal endothelial cells (mEC) used as a positive control (Fig. 1c) 8. However, the 
PECAM1+ fraction strongly expressed the melanocyte marker tyrosinase (Tyr) leading us to 
suspect we had enriched a previously unidentified PECAM1+ subpopulation of melanoma 
cells from the B16F10 cell line. To test this possibility, we engrafted parental B16F10-GFP 
tumor cells into wild type, C57BL/6 mice and unlabeled B16F10 cells into C57BL/6-
Tg(CAG–EGFP)1Osb/J mice. We then used PECAM1 immunomagnetic separation to retrieve 
highly purified fractions as before. The results showed that B16F10-GFP tumor cells in a 
wild type host generated PECAM1+/GFP+ cells whereas wild type tumors in a GFP host 
generated PECAM1+/GFP− cells (Fig. 1d). These results are consistent with a tumor cell-of-
origin for the PECAM1+ cells we have isolated. Furthermore, these results appear to rule out 
the possibility of fusion between tumor cells and PECAM1+ vascular EC in this particular 
mouse tumor model.
Next, we determined the proportion of PECAM1+ tumor cells in B16F10 tumors in vivo 
using flow cytometry. Tumors were harvested once they had reached ~ 0.4 g (+/− 0.26 g, 
s.e.m.) or ~ 1.0 g (+/− 0.22 g, s.e.m.) in size. The proportion of PECAM1+ tumor cells 
remained at ~ 0.2% of the total cellular pool, irrespective of tumor size. After gating out 
CD45+ hematopoietic cells, the ratio of PECAM1+ vascular EC to PECAM1+ tumor cells 
was approximately 10:1 (Fig. 1e, f). Taken together, these results suggest that 
subpopulations of melanoma cells may express the vascular cell adhesion molecule 
PECAM1 in vivo.
Isolation of PECAM1+ clonal populations from B16F10 melanoma
PECAM1+ cells comprised a minor fraction of B16F10 cultures and could not be easily 
detected by flow cytometry. However, occasional clusters of PECAM1+ cells could be 
found under fluorescence microscopy when B16F10 cultures were directly stained with 
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PECAM1 antibodies (Supplementary Fig. 1a). To further explore the significance and 
biological functions of PECAM1+ melanoma cells, we prepared clonal populations using 
limiting dilution assays from highly enriched PECAM1+ fractions (Fig. 2a). In 50% 
enriched fractions, PECAM1+ tumor cells were visible as large, flattened colonies that were 
distinct in appearance from spindle-shaped, PECAM1− tumor cells (Supplementary Fig. 1b). 
These PECAM1+ tumor cells could be cleanly separated from their PECAM1− counterparts 
using cloning rings or multiple rounds of immunomagnetic separation with PECAM1 
antibodies followed by limiting dilution assays. qPCR using clonally-derived populations 
revealed robust Pecam1 mRNA expression in clones A2 and A5 but not in clone A1 (Fig. 
2b). No mRNAs were detected for VE-cadherin or Vegfr-2 in PECAM1− or PECAM1+ 
tumor cells. Tyr was expressed by all melanoma cells but not mEC, as expected. Confocal 
microscopy revealed that PECAM1 was concentrated at the cell membrane in mEC but was 
diffusely localized at the membrane and throughout the cytoplasm in PECAM1+ tumor cells 
(Supplementary Fig. 1c). Western blotting confirmed a migrating band at the expected size 
for murine PECAM1 in PECAM1+ clones (Fig. 2c). PECAM1 was tyrosine phosphorylated 
in PECAM1+ tumor cells suggesting it may have similar signaling abilities in both EC and 
tumor cells (Supplementary Fig. 1d).
PECAM1+ melanoma cells generate PECAM1+ progeny
We found that PECAM1 expression in PECAM1+ clones was stable in vitro and was not 
diminished by growth in different culture media (Supplementary Fig. 2a). However, cell-
surface PECAM1 was reduced by > 50% when PECAM1+ tumor cells were detached from 
tissue culture dishes using trypsin as opposed to accutase which does not affect PECAM1 
surface expression (Supplementary Fig. 2b). Additionally, routine passaging of cells did not 
diminish PECAM1 expression (Supplementary Fig. 2c). Interestingly, PECAM1+ tumor 
cells displayed a slight growth delay in vitro and in vivo when engrafted into mice 
(Supplementary Fig. 2d). Long-term in vitro propagation of PECAM1− and PECAM1+ 
tumor cells revealed that PECAM1+ tumor cells generally give rise to PECAM1+ progeny 
and vice versa (Supplementary Fig. 2e). To determine the fate of PECAM1− and PECAM1+ 
tumor cells in vivo, we transduced PECAM1+ and PECAM1− tumor cells with GFP using 
lentivirus to generate PECAM1+/GFP+ (clone A5) or PECAM1−/GFP+ (clone A1) lines. We 
then injected 1.0 × 106 tumor cells subcutaneously in wild type C57BL/6 mice. Flow 
cytometry of collagenase-dispersed tumors revealed that, in general, PECAM1+ tumor cells 
generate PECAM1+ progeny whereas PECAM1− tumor cells generate mostly PECAM1− 
progeny (Supplementary Fig. 2f). When quantified by flow cytometry, PECAM1− tumors 
generated a mixed population consisting of ~ 2% PECAM1+ progeny and ~ 98% PECAM1− 
progeny. These results suggest that PECAM1− and PECAM1+ melanoma cells are stable 
subpopulations but may generate their counterparts at low frequencies with a tendency for 
PECAM1− tumor cells to generate PECAM1+ progeny. Finally, karyotypes performed on 
PECAM1+ and PECAM1− clones showed that PECAM1− tumor cells were more variable in 
chromosome counts with a median chromosome number of 70 whereas PECAM1+ tumor 
cells had a median chromosome count of 64 (Supplementary Fig. 3a, b). Both PECAM1− 
and PECAM1+ clones displayed similar marker chromosomes to those observed in 
previously published reports of the B16 cell line 29,30. This result, in addition to the shared 
chromosomal aberrations between the two populations, suggests that the PECAM1+ fraction 
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may have persisted and been continuously generated at a low frequency within the B16F10 
cell line for decades.
In vitro vascular properties of PECAM+ melanoma
To further characterize established PECAM1+ clones, we carried out a microarray analysis 
using an Affymetrix mouse gene ST1.0 platform. A complete microarray dataset showing 
differentially expressed genes in PECAM1− and PECAM1+ tumor cells has been uploaded 
to the Gene Expression Omnibus (GEO). Notably, microarray analysis showed an 
enrichment of additional candidate genes associated with known vascular functions in 
PECAM1+ clones (A2, A3, A4, A5) compared to parental B16F10 tumor cells. These genes 
included Ephb4, Bmpr2, Pdgfa, Icam1 (CD54), Thbs1, Bmp1, Rbpj1, and Notch2 (Fig. 2d). 
Expression of these genes was confirmed by qPCR (Supplementary Fig. 4 and see 
Supplementary Table 1 for a complete list of PCR primer sets).
Because PECAM1 is a cell adhesion molecule known to mediate in vitro tube formation of 
bona fide EC, we assessed whether PECAM1+ melanoma cells might also undergo in vitro 
tube formation 31,32. PECAM1+ tumor cells displayed a 4–5 fold increase in branching tube-
like networks compared to their PECAM1− counterparts. PECAM1− tumor cells only 
formed occasional tube-like structures which were not stable in culture. Tube like-structures 
in PECAM1+ tumor cells could be inhibited by ~ 50% using a PECAM1 blocking antibody 
indicating a functional role for PECAM1 in this assay (Fig. 2e) 33. Gain of function 
experiments showed that PECAM1 over-expression (OE) in PECAM1− tumor cells (clone 
A1) stimulated in vitro tube formation ~ 4-fold whereas PECAM1 shRNA in PECAM1+ 
tumors cells (clone A5) diminished tube formation by ~ 50% (Fig. 2f, g, h, i). These results 
suggest that PECAM1 is a marker of a unique subpopulation of B16F10 tumor cells and it 
plays a functional role in the establishment and stability of in vitro tube-like networks.
PECAM1+ tumor cells exist in spontaneous murine melanoma
Next, we turned to the ΔBraf/Pten−/− genetically-engineered mouse model of melanoma to 
assess whether PECAM1+ tumor cells were present in spontaneous tumors (Fig. 3a) 34. First, 
we measured Pecam1 mRNA expression using qPCR in two cell lines recently derived from 
tumors in ΔBraf/Pten−/− mice 35. The results showed that Pecam1 mRNA levels were above 
the zero transcript threshold we established using a known PECAM1− clone derived from 
B16F10 (clone A1) (Fig. 3b). These results suggested that, similar to B16F10, a minor 
subpopulation of PECAM1+ tumor cells might be present within ΔBraf/Pten−/− tumor cells. 
To address this possibility, we used PECAM1-mediated immunomagnetic enrichment in 
PBT2460 tumor cells and found that after six enrichment steps, about 15% of the population 
expressed PECAM1 on the cell surface by flow cytometry. After two additional enrichment 
steps, about 98% of the population expressed PECAM1 (Fig. 3c). qPCR confirmed an ~ 
100-fold increase in Pecam1 mRNA in the enriched fraction when compared to the un-
enriched parental population but VE-cadherin and Vegfr-2 were absent from both 
populations (Fig. 3d). Notably, these PECAM1+ cells derived from ΔBraf/Pten−/− tumors 
were not identical to those obtained from B16F10; namely, unlike PECAM1+ cells from 
B16F10 melanoma, they did not express ICAM1 protein or mRNA by qPCR 
(Supplementary Fig. 5a, b).
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Using the enriched PECAM1+ fraction from ΔBraf/Pten−/− tumors, we generated single-cell 
clones by limiting dilution assays. Similar to PECAM1+ tumor cells derived from B16F10, 
single cell clones derived from ΔBraf/Pten−/− tumors maintained PECAM1 expression in 
culture that was detectable on the cell surface by flow cytometry (Fig. 3e). Furthermore, 
clonally-derived PECAM1+ tumor cells from ΔBraf/Pten−/− tumors showed a five-fold 
increase in the formation of vascular-like networks in vitro compared to their PECAM1− 
counterparts (Fig. 3f). As with B16F10-derived PECAM1+ tumor cells, these tube-like 
structures were stable over time but could be diminished by ~ 50% using a PECAM1 
neutralizing antibody (Fig. 3g, Supplementary Movie 1).
PECAM1+ melanoma cells integrate into vessel lumens in vivo
To assess whether PECAM1+ melanoma cells generated vessel-like structures in vivo, we 
engrafted unlabeled, clonally-derived PECAM1+ (clone A5) and PECAM1− (clone A1) 
melanoma cells under the skin of C57BL6/J mice. We then stained cryosections with 
antibodies against PECAM1 and the melanoma marker S100B 36. Strikingly, in PECAM1+ 
tumors, we found intra-tumoral holes and channels lined by PECAM1+/S100B+ tumor cells 
(Fig. 4a). These channels appeared to be formed entirely by PECAM1+/S100B+ tumor cells 
(top row) or were formed in collaboration with PECAM1+/S100B+ tumor cells and host 
endothelium (middle row). In contrast, PECAM1− tumors were characterized by host-
derived PECAM1+ vasculature juxtaposed to S100B+ tumor cells (bottom row). Next, we 
used GFP-labeled PECAM1+ and PECAM1− clonally-derived populations from B16F10 to 
further assess the localization of PECAM1− and PECAM1+ tumor cells in vivo by 
immunohistochemistry. Similar to the results above, in PECAM1+ tumors, co-staining using 
PECAM1 and GFP antibodies revealed large openings, intratumoral channels, and vascular-
like structures that incorporated GFP+ tumor cells within their lumens (Fig. 4b, first row). In 
contrast, host-derived PECAM1+ vascular EC were mainly peripheral to GFP+ tumor cells 
in PECAM1− tumors (Fig. 4b, second row). We then determined whether PECAM1+ tumor 
cells were also incorporated into VE-cadherin+ vascular lumens. Similar to the staining 
pattern for PECAM1 above, we found that PECAM1+ tumor cells formed mosaic vascular 
structures and were incorporated within occasional VE-cadherin+ lumens (Fig. 4b, third 
row). In contrast, PECAM1− counterpart tumor cells were localized to the margins of host-
derived VE-cadherin+ blood vessels (Fig. 4b, fourth row). Taken together, these results 
suggest that PECAM1+ melanoma cells have vascular-like properties including the ability to 
spontaneously organize into tube-like structures in vitro and incorporate into vascular 
lumens in vivo.
PECAM1+ melanoma form perfused vascular structures in mice
To determine whether PECAM1+ tumor cells were in direct contact with the host 
circulation, we examined paraffin-embedded tumor sections stained with GFP antibodies 
visualized using 3,3′ diaminobenzidine (DAB). The results showed numerous channels or 
“lumens” that were comprised of GFP+ tumor cells in direct contact with erythrocytes (Fig. 
5a). H & E stained sections showed large dilated vessels, hemorrhage, and blood-filled 
channels in PECAM1+ tumors versus their PECAM1− counterparts (Fig. 5b). When 
quantified using the ImageJ software package, the mean hemorrhage area for PECAM1− 
tumors was 46.7 AU +/− 1.3 and 88.3 AU +/− 23.0 for PECAM1+ tumors (Fig. 5b, lower 
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panel). In support of a PECAM1-dependent form of VM in this model, this increase in 
hemorrhage area was diminished when PECAM1+ tumors were engrafted in PECAM1 KO 
mice (Supplementary Fig. 6a, b, c).
Next, we carried out 3D acoustic angiography and dynamic contrast-enhanced perfusion 
imaging using lipid-encapsulated micro-bubble contrast agents to measure real-time tumor 
perfusion and vascular structure in PECAM1− and PECAM1+ tumors (Fig. 5c, left) 37. Dual-
frequency, 3D acoustic angiography revealed mean volumetric vascular density values of 
47.9 +/− 2.9 for PECAM1− tumors, whereas PECAM1+ tumors had mean volumetric 
vascular density values of 72.3 +/− 5.5 (Fig. 5c, middle). The sample means were 
statistically significant when analyzed using a two tailed t-test. We observed that the 
acoustic angiography images showed the presence of greater sub-resolution contrast in 
PECAM1+ compared to PECAM1− tumors. This sub-resolution contrast signal likely 
emanates from pooling blood, which could correspond with the larger hemorrhage areas 
observed in PECAM1+ tumors. Additionally, destruction-reperfusion images acquired 
longitudinally were used to compute the area-normalized relative blood volume (normalized 
RBV) analyzed using a linear mixed effects model in R. The area-normalized RBV 
regression intercept was 3.46 +/− 2.95 units for PECAM1− tumors and 15.60 +/− 4.76 units 
for PECAM1+ tumors which was statistically significant (Fig. 5c, right). Overall, these 
results demonstrate that the normalized RBV of PECAM1+ tumors was an average of 4.5 
times higher than that of PECAM1− tumors.
To determine whether PECAM1+ tumor cells were in contact with the circulation, we 
injected Texas Red-labeled high molecular weight Dextran (TR-Dextran) by way of the tail 
vein in mice bearing PECAM1−/GFP+ or PECAM1+/GFP+ tumors 38. GFP+ tumor cells in 
direct contact with TR-Dextran were then analyzed using confocal microscopy (Fig. 5d). 
After analyzing multiple sections from 3–4 mice/group, we found a six-fold increase in 
PECAM1+ tumor cells in contact with TR-Dextran when compared to their PECAM1− 
counterparts. These results were confirmed in an additional PECAM1+ clone (clone A2) 
(Supplementary Fig. 7a, b, Supplementary Movies 2, 3). Finally, we carried out transmission 
electron microscopy (TEM) of engrafted PECAM1− and PECAM1+ tumors. The 
ultrastructure of vessels in these tumors showed melanoma cells (identified by the presence 
of melanosomes, a unique feature of melanocytes and melanoma cells) in direct contact with 
the basal lamina of erythrocyte-containing vessels in PECAM1+ tumors, but this contact was 
rarely seen in PECAM1− tumors (Supplementary Fig. 8). Thus, these results suggest that 
PECAM1+ tumor cells organize into primitive vascular channels that may be affiliated with 
the host circulation and perfused with blood.
AP-2α is reduced in PECAM1+ tumor cells and represses PECAM1
Next, we asked how PECAM1 expression was transcriptionally-regulated in PECAM1+ 
tumor cells. Notably, we did not find evidence for epigenetic regulation of Pecam1 
expression in B16F10 because neither the DNA methyltransferase inhibitor 5-azacytidine 
nor the pan-HDAC inhibitor TSA could induce Pecam1 mRNA (Supplementary Fig. 9a). 
However, PECAM1 is known to be regulated by the transcription factor GATA2 and 
additional binding sites in the PECAM1 promoter for SP1, ETS, and AP-2α are also 
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reported 39. We scanned the PECAM1 promoter and used semi-quantitative RT-PCR to 
measure the expression of these candidate transcription factors in PECAM1− and PECAM1+ 
clones. The results showed that unsorted B16F10 melanoma and clonally-derived 
PECAM1− or PECAM1+ tumor cells either did not express or expressed similar levels of 
most of these transcription factors, including Ets (Fig. 6a). On the other hand, Ap-2α 
expression was strikingly diminished in PECAM1+ tumor cells and mEC but was expressed 
in unsorted B16F10 cells and PECAM1− tumor cells. Ap-2α expression was similar in 
parental B16F0, the low-metastatic B16 clone B16F1, B16F10, and two independent 
PECAM1− clones (Supplementary Fig. 9b). Expression of the well-characterized melanoma 
markers dopachrome tautomerase (Dct) and micropthalmia-associated transcription factor 
(Mitf-m) were also similar in these same cell lines at the mRNA and protein levels 
(Supplementary Fig. 9b, c). Interestingly, PECAM1+ clones consistently produced more 
pigmented cells in vitro and highly pigmented tumors in vivo despite expressing similar 
levels of Tyr and Dct compared to PECAM1− counterparts (Supplementary Fig. 9d, e).
Because AP-2α levels were inversely correlated with PECAM1, we hypothesized that 
AP-2α might function as a transcriptional repressor of PECAM1. We used chromatin 
immunoprecipitation (ChIP) to confirm that AP-2α occupied the PECAM1 promoter in 
B16F10 tumor cells. Immunoprecipitation with an AP-2α antibody followed by PCR using 
two primer sets unique to the mouse PECAM1 promoter revealed amplified fragments of the 
predicted sizes (Fig. 6b). Furthermore, PECAM1− tumor cells transfected with Ap-2α 
siRNA revealed up-regulation of Pecam1 mRNA and protein expression, which was 
accompanied by a four-fold increase in tube formation in Matrigel (Fig. 6c, d). On the other 
hand, stable lentiviral re-expression of Ap-2α into PECAM1+ tumor cells resulted in down-
regulation of Pecam1 mRNA and protein expression, and a 6-fold reduction in tube 
formation (Fig. 6e, f, Supplementary Movie 4). These results suggest that AP-2α may 
repress PECAM1 expression and that diminished expression of AP-2α in PECAM1+ 
B16F10 cells accompanies their ability to form vascular like structures in vitro.
PECAM1+ tumor cells are enriched after anti-VEGF therapy
Because PECAM1+ tumor cells do not express VEGFR-2, but engage in VM, we 
hypothesized they might form VEGF-independent intratumoral channels in mice. First, we 
subjected mice bearing B16F10-GFP tumors to MCR84, a neutralizing antibody raised 
against VEGF-A, and then harvested tumors once they become refractory to further 
treatment (Fig. 7a) 40,41. MCR84-treated mice demonstrated a characteristic delay in tumor 
growth, followed by tumor regrowth that was resistant to further VEGF inhibition (Fig. 7b). 
We then used flow cytometry to measure the proportion of GFP+/PECAM1+ tumor cells in 
size-matched tumors. We found that in size-matched, MCR84-resistant tumors, the number 
of PECAM1+ tumor cells was enriched ~ 6 fold whereas PECAM1− tumor cells and bona 
fide EC were marginally reduced (Fig. 7c, d). To examine the specific role of PECAM1+ 
tumor cells in tumor responses to anti-angiogenic therapy, we engrafted GFP-labeled 
clonally-derived populations of either PECAM1+ or PECAM1− tumor cells into C57BL6/J 
mice. Mice were then treated with MCR84 as described above. We found that PECAM1− 
tumors demonstrated an expected delay in tumor growth and reduction in tumor volume (~ 
two-fold decrease in tumor volume at day 15) when challenged with MCR84. On the other 
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hand, PECAM1+ tumors showed no appreciable growth inhibition compared to controls 
(Fig. 7e). H & E and GFP-stained tissue sections revealed striking differences in blood 
vessel morphology and numerous blood-filled “channels” encapsulated by GFP+ tumor cells 
in the PECAM1+ tumors challenged with MCR84 (Fig. 7f). Taken together, VEGF blockade 
induces expansion of a minor subpopulation of PECAM1+ melanoma cells; furthermore, 
PECAM1+ melanoma cells form tumors that do not respond to VEGF inhibition and they 
generate aberrant vascular-like structures following challenge with VEGF blocking 
antibodies.
Human melanoma contains a PECAM1+ subpopulation
We examined PECAM1 expression from microarray data generated from > 40 human 
melanoma cell lines and normal human melanocytes 42. From these data, we identified 
approximately 10 cell lines which fell above a threshold (~ 1.5 adjusted mean fluorescence 
values from microarray data) established using normal human melanocytes which do not 
express PECAM1 (Fig. 8a). A list of normal melanocytes and melanoma cells along with the 
raw fluorescence values from the microarray are shown in Supplementary Table 2. We 
began by culturing some of the highest PECAM1-expressing cell lines and measuring 
PECAM1 mRNA levels by quantitative RT-PCR. The results showed that, as predicted from 
the microarray analysis, PECAM1 mRNA was detected in the WM2664, MEL505, 
RPMI7951, WM1158, and SBCl2 cell lines albeit at vey low levels compared to human EC 
(hEC) (Fig. 8b). No PECAM1 transcripts were detected in normal melanocytes, RPMI8332, 
or SKMEL119 which all fell below the established threshold on the microarray. On the other 
hand, VE-CADHERIN mRNA, which is expressed in some uveal forms of melanoma that 
engage in vasculogenic mimicry, was not detected in most cell lines but was found at very 
low levels in WM1158 cells 43. Using flow cytometry, we could detect a minor shift in 
PECAM1 fluorescence in RPMI7951 (3.3%) and WM1158 cells (1.6%) but a much larger 
shift in SBCl2 cells (50%). No PECAM1 surface expression was detected in normal 
melanocytes (NHM7) or in RPMI8332, as expected (Fig. 8c). Similar to the PECAM1+ 
fractions derived from murine B16F10 and ΔBraf/Pten−/− cells, SBCl2 melanoma cells 
formed robust and stable vessel-like networks in vitro which were inhibited by PECAM1 
neutralizing antibodies (Fig. 8d, Supplementary Movie 5).
Because SBCl2 expressed detectable PECAM1 levels by flow cytometry, we engrafted this 
cell line subcutaneously in NOD-SCID-γ (NSG) mice. We then stained primary, paraffin-
embedded SBCl2 tumors with PECAM1 antibodies that were verified to be human specific 
using western blotting and immunohistochemistry (Supplementary Fig. 10a, b). While the 
majority of PECAM1+ tumor cells detected with human antibodies appeared randomly 
scattered throughout the tumor, occasional PECAM1+ “lumens” were also visible (Fig. 8e). 
Overall, PECAM1+ tumor cells were found at the luminal and abluminal surface of vascular 
structures (white arrowheads), and were detected in all SBCl2 tumors examined, and were 
present at an average density of ~ 5 vessel-like structures per mm2 when normalized to 
tumor size for each tissue section (Fig. 8e, far right). Thus, similar to mouse melanoma, a 
subpopulation of some human melanoma cells express PECAM1 and engage in the 
formation of vascular-like structures in vitro and in vivo.
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We have identified a subpopulation of PECAM1+ melanoma cells that was “hidden” within 
heterogeneous and predominantly PECAM1− melanoma tumors. Generally, PECAM1+ 
melanoma cells were more motile and coalescent in Matrigel which could be reversed by 
introduction of the AP-2α transcription factor. However, PECAM1 expression was only 
partially repressed upon AP-2α introduction, indicating additional factors regulate PECAM1 
expression in melanoma cells. Furthermore, the nature of the AP-2α defect in PECAM1+ 
tumor cells is not yet clear and its diminished expression in these cells could be due to 
mutations, epigenetic silencing, or other unknown mechanisms. AP-2α is a putative tumor 
suppressor shown to act as a transcriptional repressor of melanoma cell adhesion molecule 
(MCAM) and activator of KIT 44,45. AP-2α also controls melanoma cell motility and its 
expression is diminished in aggressive forms of melanoma and breast cancer 46,47. 
Consistent with a role for AP-2α in cellular movement, we found that introduction of AP-2α 
into PECAM1+ tumor cells completely blocked in vitro tube formation, a process involving 
cellular migration and stable intercellular connections.
PECAM1+ tumor cells were present within the B16F10 population in low abundance, and 
we were unable to detect PECAM1 expression in the low-metastatic B16 clone B16F1. 
However, it is possible that an infrequent population of VM-competent tumor cells could 
also be enriched from these cell lines in nascent tumors or at sites of metastasis. For 
example, a minor population of PECAM1+ tumor cells could assist during initial tumor 
neovascularization (when tumors are relatively small and have yet to recruit an efficient 
blood supply) by forming transient vascular channels that conduct blood or fluid. 
Remarkably, this concept was first suggested over 40 years ago in studies using melanoma 
transplants in the hamster cheek pouch 48. It is also possible that not all “channels” formed 
by PECAM1-lined structures contain flowing blood and may thus resemble “blood lakes” 
described previously 49. Whether or not these “blood lakes” are inert reservoirs or play an 
active, pathophysiological role in tumor progression remains unclear. VM-competent tumor 
cells could also be generated due to selection pressure (differentiation from PECAM1− 
counterparts) or mobilized in tumors challenged with angiogenesis inhibitors. Indeed, we 
found an ~ 6-fold enrichment of PECAM1+ tumor cells in B16F10 tumors challenged with 
the VEGF blocking antibody, MCR84. PECAM1+/VEGFR-2− tumor cells could therefore 
supplant vascular EC lost following treatment with anti-angiogenic therapy and form 
PECAM1-dependent “bridges” between neighboring tumor cells and EC (Fig. 9a, b).
We found that PECAM1 blocking antibodies could reduce the tube forming ability of 
PECAM1+ tumor cells as they do in cultured EC 31. Notably, PECAM1 introduction into 
mesothelioma cells (which do not express PECAM1) also induces robust tube formation in 
Matrigel 32. PECAM1 is required for tube formation in bona fide EC, whereas VE-cadherin 
mediates both cell-cell adhesion and vacuole fusion 50. Thus, PECAM1 expression in 
melanoma may mediate cell elongation, migration, and invasion while stabilizing the 
junctional, homophilic complexes between neighboring cells necessary to create a patent 
lumen 51. Taken together, our model is rather different from a passive process of tumor cell-
to-EC mosaicism observed in other tumor types 52,53. Instead, co-option of PECAM1 by 
tumor cells may actively stabilize cell-cell interactions between PECAM1+ tumor cells and 
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between PECAM1+ tumor cells and EC. PECAM1 is typically concentrated at cell-cell 
borders by a process known as “diffusion trapping” which leads to cell aggregation where 
two PECAM1+ cells meet 54. Indeed, homophilic PECAM1-PECAM1 binding was 
suggested, many years ago, to mediate in vitro tumor cell adhesion to EC in co-culture 
studies 55.
Given the role of PECAM1 in mediating diapedesis (transendothelial migration) by 
inflammatory cells, it may be interesting to revisit recent studies demonstrating distinct 
mechanisms of metastasis using the B16F10 model to determine if subpopulations of 
PECAM1+ tumor cells are involved 56. We found PECAM1 tyrosine phosphorylation in 
melanoma cells, suggesting PECAM1-mediated signal transduction could function 
analogously in EC and in PECAM1+ melanoma cells. In support of this possibility, clonal 
populations of PECAM1+ melanoma displayed a slight growth delay compared to 
PECAM1− counterparts suggesting that PECAM1-PECAM1 interactions between tumor 
cells could stimulate contact inhibition, as it does in EC, and a slower rate of growth despite 
their ability to form vascular-like channels in vivo. It is therefore possible that acquisition of 
vascular-like characteristics by tumor cells could come at the expense of reduced 
tumorigenicity overall. Taken together, the PECAM1+ population of melanoma cells we 
have uncovered could play multiple roles in diverse processes related to melanoma 
development, dormancy, migration/invasion, and angiogenesis.
Methods
Mice
For studies using the B16F10 melanoma cell lines, female C57BL6/J mice were used 
(Jackson Laboratories, Bar Harbor, ME). Mice were injected with tumor cells at 7–8 weeks 
of age. For engraftment of human melanoma cells, we used female NSG mice (7–8 weeks of 
age) provided by the mouse phase I unit at UNC. C57BL/6-Tg (CAG-EGFP)1Osb/J mice were 
purchased from Jackson Laboratories, Bar Harbor, ME). Pecam1 knockout mice were 
kindly provided by Dr. E. Tzima (UNC Chapel Hill), and tumor cells were engrafted in 
female mice at 7–8 weeks of age. All mouse experiments were carried out in accordance 
with protocols approved by the Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill.
Cell lines and media
B16F0, B16F1, B16F10 (ATCC), ΔBraf/Pten−/− (derived from B6.Cg-
Braftm1MmcmPtentm1HwuTg(Tyr-cre/ERT2)13Bos/BosJ mice (UNC-Chapel Hill Mouse Phase 1 
Unit)) cell lines PBT2460 and PBT2130 (Drs. W. Kim and J. Bear, UNC-Chapel Hill), and 
human melanoma cell lines WM1158, SBCl2, Sk-Mel-119, Sk-Mel-173, and WM2664 (Dr. 
J. Shields, UNC-Chapel Hill) were maintained in DMEM with 4.5 g/mL D-Glucose and 
10% FBS. Human melanoma cell lines RPMI7951, RPMI8322, and Mel505 (Dr. J Shields, 
UNC-Chapel Hill) were maintained in RPMI with 10% FBS. The normal human melanocyte 
line NHM7 (Dr. J Shields, UNC-Chapel Hill) was maintained in Media 254 (Gibco) 
supplemented with HGMS (Gibco). EC (isolated by us previously 8) were maintained in 
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Endothelial Cell Media (EC-Media), composed of DMEM with 1g/L glucose, 5 μg/L bFGF, 
10 μg/L VEGF, 100 mg/L heparin, antibiotics, and 10% NuSerum IV (BD).
Antibodies
For a complete list of antibodies and dilutions used, please refer to Supplementary Table 3.
Western blotting
Whole cell lysates were prepared in radioimmunoprecipitation assay buffer (RIPA, Boston 
BioProducts), separated by SDS-PAGE at 100V using a Bio-Rad 4–20% TGX gel (Bio-
Rad), blocked with 5% Milk-TBS-T for standard western blotting, 5% BSA for phospo-
VEGFR2 blotting, and probed with antibodies overnight at 4°C. Peroxidase-conjugated 
secondary antibodies were incubated at RT for 1 hour, and bands were exposed with 
Western Lightning (PerkinElmer). Blots were imaged on a Fluorchem M (ProteinSimple). 
All antibodies and dilutions are presented in Supplementary Table 3. Uncropped western 
blots are presented in Supplementary Fig. 11.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed using the ChIPit Express Kit (Active Motif) according to 
the manufacturer’s instructions. 2 μg anti-AP-2α antibodies were used for 
immunoprecipitation and bound DNA was analyzed using two primer sets designed against 
the mouse PECAM1 promoter (for sequences see Supplementary Table 1).
siRNA Knockdown
Cells were plated at 2.0 ×105 cells/well in 6-well plates. siRNA SmartPools (Dharmacon) 
targeting Ap- 2α (M-062788-01-0005), Pecam1 (TRC RMM4534-EG18613), or non-
targeting controls (D-001206-13-05) were added to plates the next day according to the 
manufacturer’s instructions at a concentration of 100 nM. Cells were allowed to grow for 48 
hours before harvesting.
Isolation of PECAM1+ tumor cells
Tumors were harvested and prepared for cell isolation as previously described by us 8,57. In 
brief, tumors were minced in cold DMEM with 1 g/L glucose. Tumors were further digested 
using a mechanical tissue homogenizer (Miltenyi). Samples were incubated at 37°C with 5 
ml Collagenase T2 (2 mg/ml, Worthington), 1 mL neutral buffered protease (2.5 U/ml, 
Worthington), and 75 μL deoxyribonuclease (1 mg/mL, Worthington) for 75 minutes. Red 
blood cells were lysed with 1X Pharmlyse B (BD PharMingen). Cells were suspended in 
FACS Buffer (degassed phosphate-buffered saline containing 2 mM EDTA and 0.5% BSA), 
Fc receptors were blocked with Fc Block (Miltenyi), and 10 μg PE-conjugated anti-
PECAM1 antibodies were added for 20 minutes. Cells were washed and resuspended with 
anti-PE magnetic beads (Miltenyi) for 15 minutes. Cells were then washed and passed over a 
magnetic column, washed, and then eluted. Eluted cells were washed and plated in EC-
Media. Cells were grown for several weeks, and the isolation was repeated until cultures 
reached ~ 99% PECAM1 positivity, at which point single cell clones were made by limiting 
dilutions.
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Tumor dissociation and flow cytometry
Single cell suspensions were prepared either from whole tumors as described above or from 
detached cell cultures as previously described by us 57. Briefly, cells were washed with PBS 
and detached using accutase (Sigma) and then labeled with fluorophore-tagged antibodies. 
Cells were then washed and fixed in FACS buffer containing 1% paraformaldehyde. Cells 
were analyzed by flow cytometry using an Accuri C6 flow cytometer running BD Accuri 
CFlow Plus Analysis software. Samples were then analyzed using the FloJo software 
package (version 10).
Immunohistochemistry
Tumors were harvested and fixed in 4% paraformaldehyde overnight at 4°C. Samples were 
then cryoprotected in 30% sucrose overnight. Samples were frozen in OCT and cut into 7 
μm sections. Slides were fixed in methanol for 20 minutes, and washed in PBS. Sections 
were blocked in 5% BSA with species-specific serum (5%) for one hour, and antibodies 
were added in blocking buffer. All antibodies and dilutions are described in Supplementary 
Table 3. Slides were incubated overnight at 4°C. Slides were washed and secondary 
antibodies were added for one hour at room temperature. Slides were counterstained with 
Vectashield Hard-set Mounting Medium with DAPI (Vector Labs). Sections were analyzed 
on a Leica DM-IRB inverted microscope or a Zeiss 710 laser scanning confocal microscope. 
Images were globally adjusted using ImageJ analysis software (http://rsb.info.nih.gov/ij) to 
enhance contrast and sharpness.
Acoustic angiography and perfusion imaging
Two methods of contrast enhanced ultrasonography were employed to quantify perfusion in 
PECAM1+ and PECAM1− tumors in vivo. Additionally, non-contrast ultrasound provided 
reference anatomical information and tumor volume. The lipid encapsulated microbubble 
contrast agents were prepared with a (9:1) molar mixture of 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC, Avanti Polar Lipids, Alabaster, AL), and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-2000] (mPEG-DSPE, 
Creative PEGWorks, Winston Salem, NC) in phosphate-buffered saline containing 15% 
(v/v) propylene glycol, and 5% (v/v) glycerol. Air in the headspace (1.5mL in a 3 mL vial) 
was exchanged with decafluorobutane (SynQuest Labs, Alachua, FL), and microbubbles 
were created by agitation with a Vialmix mixer (Bristol-Myers Squibb Medical Imaging, 
North Billerica, MA) 58. Activated microbubbles were diluted and injected intravenously 
through a tail-vein catheter at a rate of 2.8 × 107 bubbles/min. Destruction-reperfusion 
imaging was performed using a Vevo 2100 ultrasound system (VisualSonics, Toronto, 
Ontario, Canada) and dynamic contrast enhanced perfusion imaging sequences were used to 
compute relative blood volumes (VevoCQ-Advanced Contrast Quantification Software 
Analysis Tool for the Vevo 2100. VisualSonics, Toronto, Canada, © Bracco Suisse S.A. 
2010) 59. Data were normalized by tumor cross-sectional areas as defined by regions of 
interest (ROIs) drawn manually. Acoustic angiography utilizes a prototype dual-frequency 
transducer, with a low frequency element to transmit at 4 MHz, exciting microbubbles to 
produce broadband, superharmonic echoes (at a mechanical index of 0.6). The confocal high 
frequency element (30 MHz) is used to receive the microbubble response, thus avoiding 
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tissue signal and producing high-contrast, high resolution images of the tumor 
microvasculature without tissue background, in 3 dimensions 37. Acoustic angiography is 
acquired near simultaneously with b-mode soft tissue imaging, which provides anatomical 
reference. These images were used to compute the volumetric vascular density of the tumors 
using the following procedure in MATLAB (The MathWorks Inc., Natick, MA). First, ROIs 
were drawn manually to define tumor boundaries based on the b-mode images. Then, the 
ROIs were applied to mask the tumor volume in the acoustic angiography images. Finally, 
the vascular volume was computed by applying an intensity threshold cutoff, to segment the 
image into vascular and nonvascular regions. The volumetric vascular density is the ratio of 
the number of voxels classified as vascular volume over the total number of voxels in the 
tumor ROI. Statistical analysis was carried out using R (http://www.R-project.org).
Transmission electron microscopy
PECAM1+ or PECAM1− tumors were grown as described above. Tissues were harvested, 
fixed in 2.5% glutaraldehyde/2% PFA in 0.15M sodium phosphate buffer. Samples were 
post-fixed for 1 hour in 1% osmium tetroxide in 0.15M sodium phosphate buffer, 
dehydrated with a graded series of ethanol washes, treated with propylene oxide and 
embedded in PolyBed 812 epoxy resin (Polysciences, Warrington, PA). Ultrathin sections 
(70–80 nm) were cut and mounted on copper grids and stained with 4% aqueous uranyl 
acetate and Reynolds’ lead citrate. Sections were mounted to copper grids, OsO4 was used 
to stain the tissues and sections were imaged on a Zeiss Leo EM910 TEM.
Lentiviral constructs and transduction
All recombinant DNA work was carried out under approval of the Environmental Health 
Safety Division of UNC-Chapel Hill. Lentiviral expression plasmids were created by E. 
Campeau and obtained from Addgene: pLenti CMV-GFP-DEST (736-1, Addgene plasmid 
19732), pLenti CMV/TO GFP-Zeo DEST (719-1, Addgene 17431). Packaging plasmids 
psPax2 and pMD2.6 were created by Didier Trono (Addgene plasmids 12259 and 12260). 
Mouse ORF-eome constructs were acquired from the ATCC I.M.A.G.E Consortium, then 
cloned into pDONR 221 (Invitrogen) Gateway donor vectors using Clonase BP (Invitrogen). 
Cloned pDONR 221 vectors were sub-cloned into lentiviral expression vectors by Clonase 
LR reaction (Invitrogen). Lentiviral backbones were transfected with 1.5 μg packaging 
plasmids psPAX2 and pMDG2 with 15 μl Lipofectamine 2000 in 6-well plates into 
HEK293T cells. Viral particles were harvested at 24 and 48 hours post transfection. Viral 
particles were used to infect target cells with 10 μg/mL Polybrene in antibiotic-free media.
Tumor studies in mice
B16F10 melanoma cells were grown in appropriate culture medium, detached and 
resuspended in HBSS (Gibco). 1.0 × 106 tumor cells were injected subcutaneously in the 
right shoulder of C57BL6/J mice. Tumors were allowed to grow to 1 cm3 and were 
measured daily with calipers. For MCR84 studies, mice were treated intraperitoneally every 
other day with 25 mg/kg/day MCR84 or isotype control antibodies as previously 
described 41,60. Tumor sizes were measured with calipers each day. At the end of the 
experiment, mice were euthanized and tumors were harvested and weighed.
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RNA was harvested from cell lines and run on a Mouse Gene ST1.0 Chip (Affymetrix). 
Heat maps were generated using the Gene-E software package, version 2.1.134. (http://
www.broadinstitute.org/cancer/software/GENE-E/).
Polymerase chain reaction (PCR)
Primers were designed using Invitrogen Primer Perfect Design Software. End-point PCR 
was completed using a standard PCR kit (NEB). RT-qPCR was completed with Maxima 
SYBR Green (ThermoFisher) on an Applied Biosystems Step One Plus analyzer. All qPCR 
experiments were run in triplicate and data are presented as the average with the standard 
error of the mean (s.e.m.). Primer sequences used are presented in Supplementary Table 1.
Tumor hemorrhage quantification
H & E stained sections were imaged using polarized light microscopy which caused red 
blood cells (RBC) to fluoresce. Images were subsequently converted to a binary image using 
ImageJ software. The images were then thresholded to only show RBC and the “count 
particles” tool was used to analyze RBC content. The first 500 observations were binned and 
plotted.
In vitro tube-forming assays
Briefly, 50 μL Matrigel (BD) was plated in 96-well culture dishes and allowed to polymerize 
at 37°C for 30 minutes. Next, 2.5 × 104 cells/well were plated on the Matrigel layer and 
grown for 16 hours. Randomized fields were captured using a DM-IRB inverted microscope 
and tubes were quantified from each image. Data are presented as the average number of 
tubes per field +/− s.e.m. from multiple fields. For live imaging experiments Matrigel was 
plated in 24-well plates, and 5 × 104 cells/well were seeded on top of the layer. Tube 
formation was imaged on a Leica IX70 microscope outfitted with an environmental 
chamber. Data were compiled using ImageJ Analysis Software. Brightfield images were 
converted to eight-bit black and white and the “find edges” command was used to identify 
cells. Images were enhanced using sharpen tools and pseudocolored for video analysis.
Dextran perfusion
Dextran perfusion was carried out according to previously published methods 38. GFP 
labeled tumor cells were injected subcutaneously as described. Once tumors reached 1 cm3, 
mice were injected with 100 μL, 70 kD-Texas Red Dextran (Life Technologies) via the tail 
vein and sacrificed three minutes post-injection. Tumors were prepared for 
immunohistochemistry as described and imaged with a Zeiss LSM700 scanning laser 
confocal microscope. Tumor-cell affiliated dextran was quantified by identifying GFP+ cells 
abutting on dextran-lined channels in tumors and are presented as average tumor cells 
integrated within lumens per field.
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XTT Assay Kit (ATCC) was used to measure growth of cells. 5,000 cells were plated in 
triplicate in a 96 well plate. XTT reagent was prepared per manufacturers recommendations, 
added to wells, and absorbance at 475 nm was measured after 4 hours.
5-azacytadine (5-aza) and trichostatin A (TSA) treatment
5-Aza (stock: 819mM) or TSA (stock: 6.6mM) were diluted as indicated and added to 
media. Cells were harvested seven days later and RNA was purified for semi quantitative 
RT-PCR analysis.
Karyotypes
Cells were treated with 0.1 μg/mL colcemid (Irvine Scientific, Santa Ana, CA) for 3 hours to 
accumulate cells in metaphase. Cells were then treated with hypotonic 0.075M KCl for 25 
minutes at 37°C and fixed in 3:1 methanol:acetic acid. Air-dried slides were stained for G-
band analysis and at least 20 metaphase cells were counted for each cell line by the Brigham 
and Women’s Hospital CytoGenomics Core Laboratory, Boston, MA.
Statistical analysis
Statistical power for mouse experiments was calculated using Biomath (biomath.info/
power). All samples sizes were equal to or greater than recommended minimum group size. 
All measurements in mouse studies were done with the assistance of at least one blinded 
researcher for recording and confirmation. Statistical analysis was carried out using the 
Graphpad Prism 5.0f statistical analysis package unless otherwise noted. Figure legends list 
specific n and p values. Data are presented as mean ± standard error of the mean (s.e.m.).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification, isolation, and characterization of PECAM1+ tumor cells from B16F10 
melanoma
(a) PECAM1 antibodies coupled to immunomagnetic beads were used to enrich PECAM1+ 
tumor cells from collagenase-digested B16F10 tumors. (b) The enriched cells (eluate) are ~ 
99% PECAM1+ by flow cytometry. (c) Purity of the cells was further confirmed by semi-
quantitative RT-PCR. The PECAM1+ fraction from B16F10 expresses Pecam1 and Tyr, but 
not VE-cadherin. (d) Retrieval of PECAM1+/GFP+ cells from GFP tumors engrafted in WT 
hosts and PECAM1+/GFP− cells engrafted in GFP hosts. Following immunomagnetic 
separation with PECAM1 antibodies, increasing amounts of cDNA template were analyzed 
by semi-quantitative RT-PCR, indicated by the wedge. (e) Detection of PECAM1+/GFP+ 
tumor cells in vivo after injecting B16F10-GFP tumor cells into WT hosts. CD45+ 
hematopoietic cells were excluded by out-gating. The upper right quadrant are PECAM1+ 
tumor cells which comprise ~ 0.1% of each tumor. (f) The percentage of PECAM1+/GFP+ 
tumor cells are shown for two time points when tumors were different sizes (n = 3 mice per 
group). (error bars = s.e.m.)
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Figure 2. PECAM1+ clonally-derived populations from B16F10 melanoma display vascular 
characteristics and form PECAM1-dependent tube-like structures
(a) Strategy for preparation of PECAM1+ clonal populations from B16F10 melanoma using 
limiting dilutions of partially-enriched cellular fractions. (b) Characterization of PECAM1− 
and PECAM1+ clonal populations using qPCR. (c) Western blotting for PECAM1 using 
whole cell extracts from the indicated cell type. PECAM1 migrates at the expected size of ~ 
130 kDa. Blots were stripped and re-probed with β-actin antibodies to show equal loading. 
(d) Microarray analysis of parental B16F10 and PECAM1+ clonal populations derived from 
B16F10. Only known vascular or angiogenesis-related genes shown to be up-regulated in 
PECAM1+ clones are shown. (e) Images from tube-forming assay in Matrigel comparing a 
PECAM1− (A1) and PECAM1+ (A5) clone. Tube-like structures in high power fields were 
quantified and plotted. Sample means were statistically significant as determined by a 
Student’s t-test (p<0.02, n = 6 wells per condition). (f) qPCR analysis of Pecam1 expression 
in PECAM1− melanoma cells (clone A1) following ectopic PECAM1 expression. (g) 
Images of control-transfected cells and PECAM1 over-expressing cells (OE) are shown after 
a 16-hour tube formation assay and quantified at right. Means are statistically significant as 
determined by a Student’s t-test (p<0.001, n = 6–7 wells per condition). (h) qPCR analysis 
of Pecam1 expression in PECAM1+ melanoma cells (clone A5) following shRNA 
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knockdown. (i) Images of empty-vector transfected and Pecam1 shRNA-transfected cells 
are shown after a 16-hour tube formation assay and quantified at right. Means are 
statistically significant as determined by a Student’s t-test (p<0.001, n = 7–8 wells per 
condition). (scale bars = 100 μm, error bars = s.e.m.)
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Figure 3. PECAM1+/VEGFR-2− tumor cells exist in a genetically engineered mouse model of 
melanoma and they form vascular-like networks in Matrigel
(a) Examples of tumors from ΔBraf/Pten−/− mice. (b) qPCR analysis of Pecam1 expression 
in PECAM1− and PECAM1+ B16F10 clonal populations and two additional unsorted cell 
lines derived from dispersed tumors from ΔBraf/Pten−/−mice. mEC are a positive control 
for Pecam1 expression. (c) Flow cytometry analysis of unsorted (parental) PBT2460 cells 
shows ~ 3% positivity for PECAM1. After six rounds of PECAM1 selection, this fraction 
increases to ~ 15% and after eight rounds to ~ 98%. (d) qPCR analysis of the parental 
PBT2460 population versus the 8X-enriched fraction. Basal Pecam1 expression is ~ 100-
fold higher in the 8X-enriched fraction compared to unsorted PBT2460 cells, while neither 
population expresses VE-cadherin or Vegfr-2. (e) Using the 8X-enriched fraction, single cell 
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clones were prepared by limiting dilution assays and then analyzed by flow cytometry for 
PECAM1 expression. (f) Clonally-derived PECAM1+ PBT2460 cells show an ~ 5-fold 
increase in tube formation as compared to PECAM1− cells. Sample means were statistically 
significant as determined by a Student’s t-test (p<0.0001). (g) Time-lapse images of tube 
formation assay using clonally-derived PECAM1+ PBT2460 cells incubated with either a 
non-specific IgG (top row) or PECAM1-blocking antibody (bottom row). Elapsed time is 
shown in hours. At right: PECAM1 blocking antibodies reduce tube formation by ~ 50% in 
PECAM1+ PBT2460 cells. Sample means were statistically significant as determined by a 
Student’s t-test (p<0.01). (scale bars = 100 μm, error bars = s.e.m.)
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Figure 4. PECAM1+ melanoma cells integrate within vessel lumens in vivo
(a) Engraftment of unlabeled PECAM1− (clone A1) and PECAM1+ (clone A5) tumor cells 
in C57BL6/J mice. Tumors were implanted subcutaneously and then harvested ~ 3 weeks 
later. Frozen sections were stained with PECAM1 and S100b antibodies. Asterisks indicate 
blood vessels. Arrows show luminally-positioned tumor cells. (b) Representative GFP-
labeled PECAM1+ and PECAM1− tumors are shown. Sections were stained with PECAM1 
or VE-Cadherin antibodies where indicated. The boxed regions shown at far right are 
zoomed regions taken from these images. In the top panels, asterisks indicate tumor cell-
lined “channels”. The arrows show luminally-positioned tumor cells. In the bottom panels, 
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the asterisks and arrows indicate where host-derived VE-cadherin+ EC are absent but void 
space is filled by GFP+/PECAM1+ tumor cells. In PECAM1−/GFP+ tumors shown for 
comparison, PECAM1−/GFP+ tumor cells surround a host-derived, VE-cadherin+ vessel but 
do not incorporate into the lumen. (long scale bars = 100 μm, short = 20 μm)
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Figure 5. PECAM1+ melanoma cells form primitive but perfused vascular structures
(a) 3,3′ diaminobenzidine (DAB) detection of GFP antibodies used to stain tumors. 
Unlabeled B16F10 tumors implanted in wild type hosts were used as negative controls. 
Blood vessels are visible in the center of field. Unlabeled PECAM1− tumors implanted in a 
GFP host showed an expected staining pattern of host-derived blood vessels (black arrow 
heads) and stromal cells. PECAM1+/GFP+ tumor cells contained large “holes” and channels, 
some of which were blood-filled. GFP+ tumor cells in right two panels appear to be in direct 
contact with red blood cells (asterisks). The boxed area in the third panel is magnified on far 
right. Tumor area is marked with a “T” and the overlying mouse skin (GFP−) is marked with 
an “S.” Lower panel shows a second PECAM1+ clone (clone A2) with PECAM1+/GFP+ 
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tumor cells closely aligned with host blood vessels. Some unstained endothelial cell nuclei 
are also visible and are marked with white arrowheads. (b) H & E stained sections of 
PECAM1− and PECAM1+ tumors reveals large areas of hemorrhage and vessel dilation. 
Tumor sections were analyzed using ImageJ and are plotted. Sample means were 
statistically significant as determined by a Student’s t-test (p=0.0384, n = 5 tumors). (c) 
Tumor vascularity was measured using 3D acoustic angiography imaging. Means were 
statistically significant using a Welch two sample t-test (p=0.003, n = 9 for PECAM1− 
tumors and n = 8 for PECAM1+ tumors). Area-normalized relative blood volume was 
calculated from 2D destruction-reperfusion imaging. A linear mixed-effects model was used 
to calculate statistical significance (p=0.0182). (d) TR-Dextran was injected intravenously in 
mice bearing GFP-labeled PECAM1− or PECAM1+ tumors. Harvested tumors were 
sectioned and imaged on a confocal microscope. Red arrowheads point to GFP+/TR-
Dextran+ areas. Ten separate fields from tissue sections from each mouse were used to 
quantify number of tumor cells in contact with the circulation as shown. Means were 
statistically significant using an unpaired two tailed t-test, (p < 0.0001, n = 4). (scale bars = 
100 μm, short bars in high-magnification panels = 20 μm, error bars = s.e.m.)
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Figure 6. AP-2α is diminished in PECAM1+ tumor cells and is a transcriptional repressor of 
PECAM1
(a) Semi-quantitative RT-PCR analysis of Ap-2α and Ets transcription factors in PECAM1− 
and PECAM1+ clones. (b) Chromatin immunoprecipitation using B16F10 tumor cells. 
Purified genomic DNA was incubated with AP-2α antibodies followed by capture on 
protein-G agarose. Samples were analyzed by semiquantitative RT-PCR using two primer 
sets predicted to amplify different regions of the mouse Pecam1 promoter (indicated by 
arrow heads). (c) siRNA knockdown of Ap-2α. Cells were incubated for 48 hours with 100 
nM of either scrambled control (Scr. siRNA) or Ap-2α siRNA. Cell extracts were then 
evaluated by RT-PCR and western blotting. (d) Images of tube forming assay in a 
PECAM1− clone following Ap-2α siRNA knockdown. Images were taken approximately 16 
hours after seeding on Matrigel. Quantification of tube-forming ability following Ap-2α 
siRNA knockdown on right. Results are statistically significant where indicated by an 
asterisk (p<0.0001 by unpaired t-test, n = 12 observations from individual wells). (e) 
Lentiviral over-expression of Ap-2α in PECAM1+ clones. Stable cell lines were established 
from clonal populations following Ap-2α introduction and selection in Zeocin. Cell extracts 
were evaluated by RT-PCR and western blotting. (f) Images of tube forming assay in a 
PECAM1+ clone following Ap-2α lentiviral introduction. Images were taken approximately 
16 hours after seeding on Matrigel. Quantification of tube-forming ability following Ap-2α 
lentiviral introduction on right. Results are statistically significant where indicated by an 
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asterisk and were confirmed using two different derived clones (p=0.0202, n = 3–4 
observations from individual wells). (scale bars = 100 μm, error bars = s.e.m.)
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Figure 7. PECAM1+ tumor cells are enriched in tumors challenged with anti-VEGF therapy
(a) Experimental design. (b) Tumor volumes in control (n = 8) and MCR84-treated (n = 8) 
mice measured with calipers each day. MCR84 treatment was initiated where indicated. (c) 
Flow cytometry analysis of collagenase-dispersed tumors from control and MCR84-treated 
mice. Three representative dot plots from individual mice are shown. Live cells/GFP+ cells 
were selected and then gated for PECAM1. The top three panels are controls and the bottom 
three panels are MCR84-treated mice. (d) Quantification of tumor subpopulations from 
collagenase-dispersed tumors using flow cytometry (n = 5–7 mice/group). Results are 
statistically significant where indicated with an asterisk (left, p=0.0095; center, p=0.0361; 
right, n.s. = not significant) as evaluated by Student’s t-test. (e) Tumor growth in mice 
bearing PECAM1− tumors (clone A1) or PECAM1+ tumors (clone A5) challenged with 
MCR84. Drug treatment was initiated on day five and tumor sizes were measured each day 
with calipers (n = 4–5 mice per group). (f) H & E and GFP-stained tissue sections from 
MCR84-treated PECAM1− and PECAM1+ tumors. Zoomed regions (yellow insets) 
demonstrate dense pockets of PECAM1+ tumor cells surrounding a vessel lumen (also 
identified by asterisks in the accompanying GFP-stained section). (scale bars = 100 μm, 
error bars = s.e.m.)
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Figure 8. Human melanoma contains a PECAM1+ subpopulation that displays vascular-like 
characteristics
(a) Microarray analysis of normal human melanocytes (black bars) and human melanoma 
(red bars). Each cell line and the raw fluorescence intensity value from the microarray are 
listed in Supplementary Table 2. The dotted horizontal line on the graph is the threshold 
below which no PECAM1 transcripts are detected. (b) Quantitative real-time PCR analysis 
of PECAM1 and VE-CADHERIN expression in normal melanocytes and seven of the highest 
PECAM1-expressing cell lines predicted from the microarray. Except for WM1158, no VE-
CADHERIN transcripts were detected. Human endothelial cells (hEC) were used as a 
positive control. (c) Flow cytometry of selected cell lines stained with human-specific 
PECAM1 antibodies. (d) Time-lapse images of tube formation assay using the PECAM1+ 
human melanoma cell line SBCl2 incubated with either a non-specific IgG (top row) or 
PECAM1-blocking antibody (bottom row). Far right: PECAM1 blocking antibodies reduce 
tube formation by ~ 60% in PECAM1+ SBCl2 cells. Sample means were statistically 
significant as determined by a Student’s t-test (p=0.02, n = 8 wells per condition). (e) 
PECAM1+ lumens formed by SBCl2 tumors. The asterisks mark lumens and white arrow 
head shows PECAM1+ tumor cells positioned at the abluminal surface. Two sections from 
each tumor were scanned for PECAM1+ lumens and the mean values were plotted on right. 
(scale bars = 100μm, short bars in high-magnification panels = 20 μm, error bars = s.e.m.)
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Figure 9. A model for a PECAM1-dependent form of vasculogenic mimicry
(a) PECAM1 plays a well-characterized role in stabilizing junctions between EC and 
leukocytes and between two EC. Tumor cell expression of PECAM1 may also stabilize 
interactions between tumor cells (TC) and EC or between two PECAM1+ TC to form stable 
junctions. (b) In tumors where PECAM1+ tumor cells are present, VEGF-independent 
“bridges” would not be affected by anti-VEGF therapies and could supplant host 
endothelium following VEGF inhibition. “Channels” formed exclusively by PECAM1+ TC 
could also be insensitive to VEGF blockade.
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